UnitedHealth Group Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Unaudited results; financial figures are in U.S. dollars. UnitedHealth Group operates UnitedHealthcare and Optum, with reportable segments UnitedHealthcare, Optum Health, Optum Insight and Optum Rx.
Financial performance
| Metric | Q2 2023 | Q2 2022 | Change |
|---|---|---|---|
| Revenue | $92.9 billion | $80.3 billion | +16% |
| Earnings from operations | $8.1 billion | $7.1 billion | +13% |
| Net earnings attributable to common shareholders | $5.5 billion | $5.1 billion | +8% |
| Diluted EPS | $5.82 | $5.34 | +9% |
| Medical care ratio (MCR) | 83.2% | 81.5% | +1.7 percentage points |
| Operating margin | 8.7% | 8.9% | -0.2 percentage points |
For the six months ended June 30, revenue was $184.8 billion (+15% year over year), operating earnings were $16.1 billion (+15%), net earnings attributable to common shareholders were $11.1 billion (+10%), and diluted EPS was $11.77 (versus $10.61). Six-month MCR was 82.7%, compared with 81.8%; operating margin was 8.7%, compared with 8.8%.
Q2 revenue grew across both platforms: UnitedHealthcare revenue rose 13% to $70.2 billion and Optum revenue rose 25% to $56.3 billion. Operating earnings increased 13% at each platform. Optum Health revenue grew 36%, but its operating margin declined to 6.4% from 8.0%; Optum Insight revenue grew 42%, while its margin fell to 20.7% from 25.6%.
Cash flow, liquidity and debt
- Cash from operations was $27.4 billion for the first half, versus $12.2 billion a year earlier. The increase was substantially influenced by receipt in June of $11.8 billion in July CMS premium payments, recorded as unearned revenue, as well as working-capital changes.
- At June 30, cash and cash equivalents were $41.8 billion; short-term investments were $4.5 billion and long-term investments $46.0 billion. The company reported $90.1 billion in cash, cash equivalents, available-for-sale debt securities and equity securities; it stated that $1.2 billion of cash and cash equivalents was available for general corporate use.
- Short-term borrowings and current maturities of long-term debt totaled $6.3 billion; long-term debt, less current maturities, was $59.3 billion. The company had $4.4 billion of commercial paper outstanding at a weighted-average annual interest rate of 5.1%.
- Operating cash funded $8.2 billion of acquisitions, $5.0 billion of share repurchases and $3.3 billion of dividends during the first half. The company issued $6.5 billion of senior notes in March. Its credit-facility debt-to-debt-plus-shareholders’ equity ratio was approximately 40%, against a 60% covenant limit.
Material changes and management commentary
- Management attributed revenue growth mainly to more people served through Medicare Advantage and Medicaid, pricing trends, growth in Optum, and higher investment income associated primarily with higher interest rates. UnitedHealthcare served 1.6 million more people year over year.
- Medical costs rose 16% in Q2, faster than revenue. Management cited elevated care activity, particularly senior outpatient procedures, business mix and lower favorable reserve development. It said increased senior outpatient care patterns may continue.
- Management noted Medicare Advantage funding pressure: the 2024 rate notice produced an industry base-rate decrease below forward medical-cost trends, and risk-adjustment model changes are expected to reduce funding. Potential responses include cost management, provider-network changes, benefit or premium adjustments, and county-by-county decisions about plan offerings.
- Optum Health growth reflected organic value-based-care growth and acquisitions; earnings were partly offset by higher senior outpatient and behavioral-health activity and costs of serving newly added patients. Optum Rx cited specialty pharmacy growth, higher script volumes and supply-chain initiatives.
- The Board increased the annualized quarterly dividend rate to $7.52 per share from $6.60. No quantified earnings or revenue guidance is provided in the supplied filing text.
Risks, contingencies and unusual items
- Medical costs payable were $31.9 billion at quarter-end, including $22.0 billion of estimated incurred-but-not-reported claims. Reserve estimates and goodwill are identified as significant accounting estimates. First-half prior-year reserve development reduced reported medical costs by $660 million; the filing says no individual factors were significant.
- The company had approximately $5 billion of anticipated consideration for pending healthcare acquisitions, subject to regulatory approval and other customary conditions. Completed first-half business combinations involved $8.2 billion of total consideration; acquired entities’ contribution to revenue and earnings was not material through June 30.
- Legal matters and regulatory reviews include CMS risk-adjustment data validation audits and a DOJ False Claims Act case concerning risk-adjustment submissions. The company said it could not reasonably estimate the outcome of the DOJ matter; losses in certain legal or regulatory matters may also be difficult to estimate.
- Other disclosed risks include medical-cost estimation and pricing, Medicare and Medicaid policy or payment changes, competition, cybersecurity and privacy incidents, litigation and investigations, acquisition integration, investment performance and access to capital. The filing reported no material change to the risk factors in the 2022 Form 10-K.
- Available-for-sale debt securities had $3.5 billion of gross unrealized losses at June 30, primarily attributed to interest-rate increases. The company said it did not intend to sell securities in unrealized-loss positions and considered the losses temporary.
Most important facts for investors to verify
- Whether senior outpatient-care utilization and the higher MCR persist, and whether pricing and cost actions offset them.
- How the 2024 Medicare Advantage rate and risk-adjustment changes affect enrollment, benefits, margins and cash flows.
- How much of first-half operating cash flow reflects timing of the $11.8 billion CMS advance payment rather than recurring underlying cash generation.
- Progress and final purchase accounting for acquisitions, including the approximately $5 billion of pending transactions and associated regulatory approvals.
- Developments in CMS RADV audits and the DOJ risk-adjustment litigation, for which the company disclosed no estimable outcome.
- Debt, commercial-paper costs and cash available for general corporate use, alongside planned dividends and repurchases.